Abeona Therapeutics Inc. Common Stock (ABEO) is a publicly traded Healthcare sector company. As of November 9, 2026, ABEO trades at $3.82 with a market cap of $238.46M and a P/E ratio of -3.20. ABEO moved -8.39% today. Year to date, ABEO is -21.47%; over the trailing twelve months it is -0.48%. Its 52-week range spans $3.91 to $7.65. Analyst consensus is strong buy with an average price target of $22.00. Rallies surfaces ABEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ZEVASKYN revenue reaches $13.5 million as Abeona expands treatment network: Abeona’s third-quarter net loss was $4.81 million, below analysts’ $8.66 million estimate, while ZEVASKYN revenue rose 18% sequentially to $13.5 million. New treatment centers in Florida and Ohio expanded the network, though revenue was not recognized for one treatment because its batch did not meet release criteria.
| Metric | Value |
|---|---|
| Price | $3.82 |
| Market Cap | $238.46M |
| P/E Ratio | -3.20 |
| EPS | $-1.55 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.65 |
| 52-Week Low | $3.91 |
| Volume | 88.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-63.73M |
| Gross Margin | 0.00% |
4 analysts cover ABEO: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.00.